Budesonide Market Report 2026

Budesonide Market Overview

• Budesonide market size has reached to $10.26 billion in 2025 • Expected to grow to $13.72 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Impact Of Respiratory Diseases Growth On The Market • Market Trend: Market Growth Driven By Innovations In Oral And Inhaled Therapies • North America was the largest region in 2025.

What Is Covered Under Budesonide Market?

Budesonide is a corticosteroid medication used to reduce inflammation in conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (Crohn’s disease, ulcerative colitis), and allergic rhinitis. It works by suppressing the immune response and decreasing inflammation in the airways or digestive tract. The main types of budesonide are inhalation powder, aerosols, injectable suspensions, tablets, and capsules. Inhalation budesonide powder is a corticosteroid medication delivered via a dry powder inhaler to reduce inflammation in the airways for conditions. Budesonide is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used for various applications, including nose disease treatment, inflammatory bowel disease treatment, respiratory disease treatment, and other applications.

What Is The Budesonide Market Growth Forecast?

The budesonide market size is expected to see strong growth in the next few years. It will grow to $13.72 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to aging population, rising chronic inflammatory diseases, growth in generic drug usage, expansion of home-based therapies, increasing respiratory disease burden. Major trends in the forecast period include rising use of inhaled corticosteroids in chronic respiratory care, increasing adoption in inflammatory bowel disease management, growing preference for targeted localized steroid therapy, expansion of generic budesonide formulations, increased use in long-term maintenance therapy.

Global Budesonide Market Segmentation

1) By Type: Inhalation Powder, Aerosols, Tablets And Capsules 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications Subsegments: 1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI) 2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers 3) By Tablets And Capsules: Oral Tablets, Oral Capsules

What Is The Driver Of The Budesonide Market?

The increase in the prevalence of respiratory diseases is expected to propel the growth of the budesonide market going forward. Respiratory diseases refer to medical diseases that affect the organs and tissues that regulate gas exchange in air-breathing animals. The increase in the prevalence of respiratory diseases is due to rising air pollution, particularly exposure to particulate matter and allergens, which has a major impact on the prevalence of asthma and chronic obstructive lung disease. Budesonide is used in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation, improve airflow, and prevent symptoms such as wheezing and shortness of breath. For instance, in August 2025, according to the Centers for Disease Control and Prevention, a Switzerland-based public health agency, 90% of the nation’s 4.9 trillion dollars in annual health care spending is attributed to individuals with chronic and mental health conditions, with more than 84,000 Americans dying each year from heart disease or stroke and the costs associated with cardiovascular diseases projected to reach roughly 2 trillion dollars by 2050. Therefore, the increase in the prevalence of respiratory diseases will drive the growth of the budesonide industry.

Key Players In The Global Budesonide Market

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

Global Budesonide Market Trends and Insights

Major companies operating in the budesonide market are focusing on advancements in respiratory treatment, such as oral therapy, enhancing patient convenience, improving treatment adherence, and expanding therapeutic options for managing asthma and other respiratory conditions. Oral therapy budesonide is a formulation of budesonide taken by mouth, primarily used to treat inflammatory conditions. For instance, in February 2024, Takeda Pharmaceuticals, a Japan-based pharmaceutical company, announced that the Food and Drug Administration (FDA), a US-based federal agency, has authorized EOHILIA, a budesonide oral suspension, as the first and only FDA-approved oral medication for patients aged 11 and above with eosinophilic esophagitis (EoE). Additionally, the FDA approved EOHILIA 2 mg twice daily based on effectiveness and safety data from two multicenter, randomized, double-blind, parallel-group, placebo-controlled 12-week investigations in individuals aged 11 to 56 with EoE.

What Are Latest Mergers And Acquisitions In The Budesonide Market?

In March 2023, Cheplapharm Arzneimittel GmbH, a Germany-based pharmaceutical company, acquired the commercial rights of PULMICORT FLEXHALER in the US from AstraZeneca for an undisclosed amount. This acquisition aims to strengthen and diversify Cheplapharm’s portfolio by securing the rights to PULMICORT FLEXHALER, a well-established budesonide-based asthma treatment. Additionally, it allows the company to expand its presence in the U.S. pharmaceutical market while ensuring continued product availability through partnerships with local distributors. AstraZeneca is a UK-based biopharmaceutical company that focuses on developing and marketing PULMICORT for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) for budesonide.

Regional Insights

North America was the largest region in the budesonide market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Budesonide Market?

The budesonide market consists of sales of nebulizer suspension, inhalers, and nasal sprays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Budesonide Market Report 2026?

The budesonide market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the budesonide industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.